[TWST]

Following Anthropic's announcement, Twist Bio surged, driving the share price gains of AI-related peers. Based on the current stock price ($140.01), while the upward breakout above the resistance level at 126.40 is maintained, I will take profit at 126.40 and cut losses if the 80.59 support level is breached. The current stock price has broken upward through the resistance level of 126.40, so entry was considered by looking at the potential for trend continuation based on this support/resistance level. The 14-day RSI is at 69.3, approaching the overbought zone, and the moving averages are in a bullish alignment. Trading volume is 0.84 times the 20-day average, and the 7-day volatility rate is +0.4%. The initially projected return was 4.5%, but the actual return reached 13.7%, resulting in an OVERHIT rating. At the time of entry, we confirmed an RSI(14) of 69.3 and a bullish moving average alignment (stacked array), approaching the position based on the upward breakout of the 126.40 resistance line. However, news momentum related to Anthropic's announcement combined with the rising trend of the theme, exerting much stronger upward pressure than anticipated. Nevertheless, the fact that the sharp surge continued even though trading volume was relatively subdued at 0.84 times the 20-day moving average indicates that non-supply-and-demand factors (the widespread diffusion across the theme) amplified stock price volatility. Through this trade, I learned that when strong thematic catalysts and neatly aligned bullish technical indicators overlap, rather than being confined to a conservative profit-taking target, it is necessary to respond by keeping the trend's strength open-ended. In future news-driven markets, I will actively utilize a scaled profit-taking strategy to further maximize gains during periods of excess upward momentum.

Twist Bioscience's stock price has reached a 52-week high of $143.1, drawing significant market attention following the announcement of this news. If the price reaches the resistance level of $142.84, take profit; if the price falls to the support level of $80.59, cut losses. These two price levels are the resistance and support levels calculated by REPORTING, and each position is closed when the respective condition is met. On 2026-09-03, with the closing price at $128.71 remaining below the resistance level of $142.84, we judged that upside potential still remains. Although the RSI of 77.9 signals overbought conditions, we considered a buy in anticipation of a possible breakout above the resistance level, taking into account that trading volume surged to 2.28 times the 20-day average and the 7-day rate of change stood at +23.1%. RSI(14) at 77.9 (overbought territory, but strong momentum), moving averages in bullish alignment (uptrend), trading volume at 2.28x the 20-day average (expanding buying pressure), recent 7-day change of +23.1% (sustained upward price momentum) The actual result of -10.8% deviated significantly from the predicted return of 3.5%. While the expectation of a sharp price rise was somewhat supported by the recent surge in trading volume and the rising 7-day rate of change, the analysis overlooked that, despite the RSI being in overbought territory at 77.9, no breakout materialized and the stop-loss level was reached. In future trades, entry should be withheld when overbought signals appear strongly, and entry should be considered only after confirmation of a resistance breakout. In addition, it is necessary to set stop-loss levels closer to limit losses, and to take positions only after further confirming whether the surge in trading volume is sustained. None

Twist Bioscience raised its fiscal year 2026 outlook to $456 million to $457 million, projecting fourth-quarter revenue of $123 million to $124 million. If the stock price rises towards the resistance level of $104.40, I will take profits, and if the support level of $82.80 is breached, I will cut losses. We are considering an entry as the stock price is showing an upward trend towards the resistance level of $104.40, supported by a strong catalyst of an upward revision in revenue outlook. The RSI(14) is at a neutral level of 51.4, and the moving averages are in a positive alignment. The trading volume is 1.10 times the 20-day average, and the recent 7-day volatility is -2.8%. The key positive factor of an upward revision in revenue outlook was accurately captured, leading to a well-read trend in stock price increase; however, the risk of equity dilution due to the offering was overlooked, resulting in an actual return of 15.1%, significantly exceeding the forecasted return of 4.5%. Even with strong positive factors, stock price volatility may increase in the event of an offering announcement, so it is necessary to analyze the risks associated with the nature of the announcement more closely and develop a response strategy. There are past similar success cases with overlapping revenue growth keywords, including BLZE (2026-08-04), TWST (2026-08-05), and ENTG (2026-08-05).